AKT1 and liver cancer: Moreover, inhibition of Akt, downregulation of cIAP2 and suppression of HBV replication can partially restore the liver cancer cell sensitivity to sorafenib, further implying the involvement of cIAP2, Akt pathway and HBV infection in the development of sorafenib resistance.